Knowledge

The recent interest growth in Extracellular Vesicles (EVs) is governed by the potential that these cell-derived membranous nanoparticles present in terms of theranostic effect.

Developing nanotherapies faces significant formulation challenges, as seen with RNA-LNP-based therapies, which account for over 500 formulations in development, yet only four are FDA-approved.

It is now largely accepted that the intestinal microbiota plays a key role in Intestinal Bowel Diseases (IBD). There are indications that phages, the viruses infecting bacteria, but also extracellular vesicles (EVs), might play a part in this family of diseases.

Lentiviral vector (LV) clinical application involves large-scale Good Manufacturing Practice (GMP), including production purification and quality controls.

Neovacs develops mRNA-based therapies targeting chronic inflammatory diseases, such as allergies. Accurate characterization of lipid nanoparticles (LNPs) is key for ensuring stability and efficacy during manufacturing and storage

Extracellular vesicles (EVs) are an emerging therapeutic agents for regenerative medicine. In order to ensure EV-based therapies quality, EVs concentration needs to be tightly monitored throughout the bioproduction process during development and manufacturing stages.

Transfection efficiency remains a crucial hurdle in viral vector production (LV or AAV) using transfection reagent-based methods.

Lipid nanoparticle (LNP) therapy development is a challenge. Using the proper tools and metrics is a key success factor.